Dong-E-E-Jiao Co.,Ltd.

XSEC:000423 Stock Report

Market Cap: CN¥37.2b

Dong-E-E-JiaoLtd Valuation

Is 000423 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 000423 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 000423 (CN¥57.97) is trading below our estimate of fair value (CN¥86.82)

Significantly Below Fair Value: 000423 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 000423?

Key metric: As 000423 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 000423. This is calculated by dividing 000423's market cap by their current earnings.
What is 000423's PE Ratio?
PE Ratio24.5x
EarningsCN¥1.52b
Market CapCN¥37.24b

Price to Earnings Ratio vs Peers

How does 000423's PE Ratio compare to its peers?

The above table shows the PE ratio for 000423 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average44.5x
002653 Haisco Pharmaceutical Group
75.5x35.7%CN¥35.7b
600079 Humanwell Healthcare (Group)Ltd
18.4x13.7%CN¥36.7b
300765 CSPC Innovation Pharmaceutical
71.6x37.5%CN¥34.8b
000661 Changchun High-Tech Industry (Group)
12.2x16.8%CN¥45.4b
000423 Dong-E-E-JiaoLtd
24.5x13.7%CN¥37.2b

Price-To-Earnings vs Peers: 000423 is good value based on its Price-To-Earnings Ratio (24.5x) compared to the peer average (43.4x).

Price to Earnings Ratio vs Industry

How does 000423's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
000423 24.5xIndustry Avg. 29.2xNo. of Companies31PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 000423 is good value based on its Price-To-Earnings Ratio (24.5x) compared to the CN Pharmaceuticals industry average (29.7x).

Price to Earnings Ratio vs Fair Ratio

What is 000423's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

000423 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio24.5x
Fair PE Ratio27.4x

Price-To-Earnings vs Fair Ratio: 000423 is good value based on its Price-To-Earnings Ratio (24.5x) compared to the estimated Fair Price-To-Earnings Ratio (27.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 000423 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥57.97
CN¥75.95
+31.0%
10.5%CN¥85.00CN¥60.00n/a10
Nov ’25CN¥59.26
CN¥74.94
+26.5%
10.9%CN¥85.00CN¥60.00n/a9
Oct ’25CN¥61.70
CN¥76.13
+23.4%
8.1%CN¥85.00CN¥68.00n/a8
Sep ’25CN¥49.87
CN¥76.51
+53.4%
8.8%CN¥88.00CN¥68.00n/a8
Aug ’25CN¥48.74
CN¥78.60
+61.3%
6.6%CN¥88.00CN¥70.00n/a8
Jul ’25CN¥63.57
CN¥77.86
+22.5%
6.6%CN¥88.00CN¥70.00n/a7
Jun ’25CN¥67.71
CN¥77.86
+15.0%
6.6%CN¥88.00CN¥70.00n/a7
May ’25CN¥68.72
CN¥72.43
+5.4%
9.7%CN¥80.00CN¥58.00n/a7
Apr ’25CN¥63.20
CN¥67.94
+7.5%
8.2%CN¥78.19CN¥58.00n/a7
Mar ’25CN¥58.60
CN¥62.84
+7.2%
5.2%CN¥67.30CN¥58.00n/a7
Feb ’25CN¥52.50
CN¥59.01
+12.4%
14.0%CN¥67.30CN¥40.00n/a7
Jan ’25CN¥49.32
CN¥57.05
+15.7%
13.2%CN¥64.80CN¥40.00n/a7
Dec ’24CN¥50.92
CN¥57.05
+12.0%
13.2%CN¥64.80CN¥40.00n/a7
Nov ’24CN¥45.61
CN¥57.05
+25.1%
13.2%CN¥64.80CN¥40.00CN¥59.267
Oct ’24CN¥49.06
CN¥56.52
+15.2%
12.9%CN¥64.80CN¥40.00CN¥61.708
Sep ’24CN¥50.19
CN¥54.86
+9.3%
12.5%CN¥62.00CN¥40.00CN¥49.877
Aug ’24CN¥49.27
CN¥57.34
+16.4%
6.0%CN¥62.00CN¥51.00CN¥48.746
Jul ’24CN¥53.45
CN¥54.96
+2.8%
10.2%CN¥62.00CN¥45.00CN¥63.576
Jun ’24CN¥49.29
CN¥53.55
+8.6%
9.5%CN¥59.60CN¥45.00CN¥67.715
May ’24CN¥51.47
CN¥50.99
-0.9%
11.0%CN¥57.00CN¥42.10CN¥68.726
Apr ’24CN¥52.99
CN¥43.18
-18.5%
39.4%CN¥57.00CN¥7.10CN¥63.206
Mar ’24CN¥48.18
CN¥41.71
-13.4%
36.0%CN¥57.31CN¥7.10CN¥58.607
Feb ’24CN¥43.90
CN¥41.42
-5.6%
36.1%CN¥57.31CN¥7.10CN¥52.507
Jan ’24CN¥40.70
CN¥38.07
-6.5%
37.1%CN¥50.00CN¥7.10CN¥49.326
Dec ’23CN¥38.94
CN¥38.07
-2.2%
37.1%CN¥50.00CN¥7.10CN¥50.926
Nov ’23CN¥38.30
CN¥43.94
+14.7%
7.6%CN¥50.00CN¥41.19CN¥45.615

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Sichuan Kelun Pharmaceutical

CN¥47.4b

Researches, develops, manufactures, distributes, and sells pharmaceutical products in China.

2422

CN¥29.85

7D

-10.1%

1Y

7.6%

Dong-E-E-JiaoLtd

CN¥37.2b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥57.97

7D

-1.7%

1Y

17.1%

China Resources Double-Crane PharmaceuticalLtd

CN¥21.9b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥21.29

7D

-0.7%

1Y

16.7%